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S U M M A R Y
Objective: To analyze the available published data (2005–2014) describing the prevalence of multi-
morbidity in adult patients with pneumococcal disease, with a focus on the comorbidities considered by
the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and
Prevention to increase the risk of pneumococcal disease in adults (immunocompetent persons with
chronic medical conditions (at risk) and immunocompromised or immunosuppressed persons (high
risk)). An analysis of case–control and population-based surveillance studies that have evaluated risk
factors for community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) was also
performed in order to estimate the importance of risk stacking.
Methods: Studies that established the enrolment procedure for patients and reported the incidence of
multimorbidity and risk factors for CAP and/or IPD were included. In order to obtain a risk stacking value
based on the at-risk comorbidity odds ratios (OR), the multiplicative method described by Campbell was
used.
Results: Thirty-eight articles were selected, 19 for multimorbidity and 19 for risk factors for CAP/IPD.
With regard to multimorbidity, the prevalence among adults aged 65 years ranged from 23% to 98.7%
for two or more comorbidities and from 18% to 89.7% for three or more comorbidities. Diabetes (DBT),
chronic heart disease (CHD), and chronic obstructive pulmonary disease (COPD) were the three most
frequent comorbidities described (7.6–28.5%, 6.9–25.8%, and 3.8–15.4%, respectively). With regard to
risk factors, based on the multiplicative method, the hypothetical scenario of concurrence of the three
most frequent at-risk conditions (DBT + CHD + COPD) showed an OR of 7.5. In this group of patients, the
addition of smoking, another common at-risk factor for CAP (stacking four concurrent conditions)
increased the OR from 8.5 to >40. These ORs were generally similar to rates described by other authors in
persons with a high risk.
Conclusions: The ORs for CAP and IPD of patients with two or more comorbidities, with or without
smoking, were found to be similar to the ORs for CAP and IPD described in the literature for patients
currently classiﬁed as high risk. The potential impact of multiple, stacking comorbidities is
underestimated and there is a need for the risk categories for pneumococcal disease to be redeﬁned.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Streptococcus pneumoniae (pneumococcus) remains a leading
cause of serious illness among adults worldwide.1 In fact, S.
pneumoniae is the etiological agent of 30–50% of community-
acquired pneumonia (CAP), the most common clinical presentation* Corresponding author. Tel.: +54 911 2319 0619.
E-mail address: daniel.curcio@pﬁzer.com (D. Curcio).
http://dx.doi.org/10.1016/j.ijid.2015.05.003
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of pneumococcal disease (PD) in this type of patient.2,3 Invasive
pneumococcal disease (IPD) is deﬁned as an infection conﬁrmed by
the isolation of pneumococcus from a normally sterile site (e.g.,
blood). Blood cultures are positive in only 10–15% of CAP cases.4
The risk proﬁles for PD have been deﬁned by the presence of
medical conditions for which the Advisory Committee on
Immunization Practices (ACIP) currently recommends pneumo-
coccal vaccination.5 Immunocompetent persons with one or more
of the chronic medical conditions identiﬁed by the ACIP are
classiﬁed as at risk. Immunocompromised or immunosuppressedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Risk groups for pneumococcal disease—Advisory Committee on Immunization
Practices (ACIP)5
Pneumococcal
disease group
Description
At risk Chronic heart or lung disease, trisomy 21, chronic liver
disease, alcoholism, smoking, neuromuscular disorders,
prematurity/small gestational age, asthma (mild, moderate,
severe), and diabetes (insulin-dependent, non-insulin-
dependent)
High risk Immunodeﬁciency, anatomical or functional asplenia,
cochlear implant, nephrotic syndrome, chronic renal
failure, malignancy, and treatment with
immunosuppressive or radiation therapy
D. Curcio et al. / International Journal of Infectious Diseases 37 (2015) 30–35 31persons and those with a cochlear implant are classiﬁed as high
risk (Table 1).5 However, in terms of the probability of suffering PD,
some authors have recently reported that rates in immunocompe-
tent persons with two or more at-risk conditions (deﬁned as
multimorbidity) are generally similar to those in persons with high
risk conditions, and rates in persons with three or more at-risk
conditions are similar or higher than rates in persons with high-
risk conditions (risk stacking).6
This review summarizes the available published data from
2005 through 20134 describing the prevalence of multimorbidity
in adult patients, with a focus on the co-morbidities included by
the ACIP in the ‘at risk’ group. An analysis of case–control and
population-based surveillance studies that have evaluated risk
factors for CAP and IPD was also performed in order to estimate the
importance of risk stacking.
2. Methods
The data presented here are part of a larger global literature
search performed in PubMed (ﬁlters activated: published in theFigure 1. Summary of the literalast 10 years, humans, adult 19+ years) to identify studies assessing
the prevalence of multimorbidity (‘‘multimorbidity’’ AND ‘‘preva-
lence’’ OR ‘‘frequency’’) and risk factors for CAP and/or IPD ((‘‘risk
factor’’) OR ‘‘comorbidity’’) AND ‘‘pneumococcal infections’’) OR
‘‘pneumococcal infection’’) OR ‘‘pneumococcal pneumonia’’). To
ensure the retrieval of relevant articles, the search was performed
by exploring and combining medical subject headings (MeSH) and
free search terms.
At a minimum, studies had to establish the enrolment
procedure used for patient recruitment and report the incidence
of multimorbidity and risk factors for CAP of their entire cohort.
The methodological quality of articles was evaluated by three
independent reviewers. Pairs of independent researchers screened
titles and abstracts of the citations identiﬁed. They categorized
the articles as either eligible or excluded. Studies with a focus on
case series (deﬁned as studies with 100 participants), articles
without original data, vaccine and/or antibiotic efﬁcacy trials, and
studies that included pediatric patients were excluded. Further-
more, publications that reported modeling or health economics
studies without a focus on prevalence, investigations in patients
with CAP and IPD and studies for which the denominator was
unknown were also excluded.
The multiplicative method described by Campbell was used to
obtain a risk stacking value based on the at-risk factors odds ratios
(OR) for CAP and IPD published in the selected articles.7 Because
of the limited number of studies available, these analyses are
presented in a descriptive format only.
3. Results and discussion
The search strategy yielded 1197 articles for review. A ﬂow
summary of the selection process is given in Figure 1. Tables 2 and
3 present a summarized description of the 38 articles ﬁnally
selected (19 for multimorbidity and 19 for risk factors for CAP).8–45ture search and screening.
Table 2
Data on multimorbidity
Reference Country, data collection years Data source, number of cases Prevalence of multimorbidity
by age-group
Kirchberger et al.8 Germany, 1984–2001 Patient survey, n = 4127 65–94 years, 58.6%a
Marengoni et al.9 Sweden, 1987–2000 Patient database, n = 1099 77–84 years, 51.6%a
85 years, 58.5%a
Noe¨l et al.10 USA, 1997–2001 Patient survey, n = 422 >50 years, 53%a
Taylor et al.11 Australia, 2000–2003 Patient interview, n = 1651 40–59 years, 32.1%a
>65 years, 57.9%a
van Oostrom et al.12 Netherlands, 2002–2008 Electronic database, n = 52 014 55–64 years, 22.7%a
65–74 years, 39.1%a
74 years, 59.2%a
Fortin et al.13 Canada, 2003 Patient records, n = 980 45–64 years, 92.8%a
>65 years, 98.7%a
van den Bussche et al.14 Germany, 2004 Health insurance data, n = 123 224 >65 years, 73%a
>65 years, 62.1%b
Britt et al.15 Australia, 2005 Patient survey, n = 9156 45–64 years, 46.5%a
65–74 years, 74.6%a
>75 years, 83.2%a
45–64 years, 22.7%b
65–74 years, 46.0%b
>75 years, 58.2%b
Viola´n et al.16 Spain, 2006 Electronic database, n = 1 597 258 45–64 years, 52.9%a
65–74 years, 79.8%a
75 years, 87.2%a
Barnett et al.17 Scotland, 2007 Electronic database, n = 1 751 841 45–64 years, 30.4%a
65–84 years, 64.9%a
85 years, 81.5%a
Garcı´a-Olmos et al.18 Spain, 2007 Electronic database, n = 19 867 >14 years, 24.5%a
Steinman et al.19 USA, 2007–2008 Hospital database, n = 2 002 693 >65 years, 89.7%b
Prados-Torres et al.20 Spain, 2008 Electronic database, n = 275 682 45–64 years, 21%a
>65 years, 23%a
45–64 years, 12%b
>65 years, 18%b
O’Kelly et al.21 Ireland, 2008–2009 Patient records, n = 653 65–94 years, 60%a
Glynn et al.22 Ireland, 2009 Patient records, n = 3309 >50 years, 66.2%a
Rizza et al.23 Switzerland, 2009–2011 Electronic database, n = 66 212 50–59 years, 15.7%a
60–69 years, 25.8%a
70–79 years, 33.6%a
50–59 years, 6.82%b
60–69 years, 13.0%b
70–79 years, 20.0%b
Ornstein et al.24 USA, 2011 Electronic database, n = 667 379 55–64 years, 61%a
65–74 years, 74.3%a
75–84 years, 81%a
55–64 years, 72%b
65–74 years, 57.3%b
75–84 years, 67.5%b
Agborsangaya et al.25 Canada, 2012 Patient survey, n = 4803 >64 years, 63.8%a
Formiga et al.26 Spain, ND Patient interview, n = 328 >85 years, 77.1%b
ND, not deternmined.
a Two or more chronic conditions.
b Three or more chronic conditions.
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The prevalence of multimorbidity among adult patients aged
65 years was reported in 14 of the 19 articles (74%), and ranged
from 23% to 98.7% in the presence of two or more comorbidities
and from 18% to 89.7% in the presence of three or more
comorbidities.8,10–17,22–26 The prevalence in those aged <65 years
(described in only eight of the 19 articles – 42%) ranged from 15.7%
to 61% among subjects with two or more comorbidities and
from 6.8% to 72% in those who presented three or more risk
conditions.11,12,16,17,20,23,24,26
Only ﬁve of 19 articles (26.3%) provided a detailed list and
frequency of occurrence of the different comorbidities (in two
additional papers the comorbidities considered were only
listed).8,14,16,24,26 Although, the comorbid conditions covered a
broad spectrum of diseases, the deﬁned at-risk conditions diabetes
(DBT), chronic heart disease (CHD), and chronic obstructive
pulmonary disease (COPD) were the three most frequentcomorbidities described (ranging from 7.6% to 28.5%, 6.9% to
25.8%, and 3.8% to 15.4%, respectively) (Figure 2).8,14,16,24,26
Speciﬁc disease combinations (co-occurrence) were also
studied in seven of 19 articles (37%).12,14,15,18–21 Individuals aged
55 years had DBT, CHD, and COPD as a unique comorbidity in only
27%, 20%, and 16% of cases.12 In this population, the co-occurrence
of DBT (as the index disease) + CHD (with or without hyperten-
sion), DBT (as the index disease) + COPD, COPD (as the index
disease) + DBT, and COPD (as the index disease) + CHD (with
or without hypertension), were described in 20.4–30%, 11–17.2%,
13–25.8%, and 14–27.4%, respectively.12,15,19
3.2. Risk factors
The ORs for the most frequent at-risk factors for CAP and IPD
(DBT, CHD, and COPD) were described in 9/19 (47%) and 1/19 (5%)
articles, respectively.29,32–35,38–40,42,45 Table 4 gives a summary of
the ORs analyzed as well as the risk stacking OR values for different
Table 3
Risk factors for pneumococcal disease: publications analyzed
Reference Country, year Type of study, number of cases Objective Measure of
association
Shea et al.27 USA, 2006–2010 Population-based adult cases, 26 362 865 Risk factors IPD and CAP RR
Kyaw et al.28 USA, 1999–2000 Case–control study, 1570:2765 Risk factors IPD RR
Vila-Co´rcoles et al.29 Spain, 2002–2005 Population-based adult cases, 11 241 Risk factors CAP OR
Thomsen et al.30 Denmark, 1992–2001 Case–control study, 598:5980 DBT for bacteremic CAP OR
Talbot et al.31 USA, 1995–2002 Case–control study, 635:6350 Asthma for IPD OR
Skull et al.32 Australia, 2000–2002 Case–control study, 1952:2927 Risk factors for CAP RR
Rodriguez-Barradas et al.33 USA, 2001–2002 Population-based adult cases, 1628 Risk factors for CAP HR
Mu¨llerova et al.34 UK, 1996–2005 Case–control study, 1469:7345 COPD for CAP OR
Klemets et al.35 Finland, 1995–2002 Case–control study, 1282:12 785 Risk factors for IPD OR
Jung et al.36 USA, 1964–1983 Case–control study, 348:174 Asthma for IPD OR
Jacups and Cheng37 Australia, 1987–2008 Population-based adult cases, 204 Risk factors for bacteremic CAP RR
Jackson et al.38 USA, 2000–2002 Case–control study, 2346:1173 Risk factors for CAP OR
Jackson et al.39 USA, 1998–2001 Population-based adult cases, 2979 Risk factors for CAP HR
Gau et al.40 USA, 2004–2006 Case–control study, 194:952 Risk factors for CAP OR
Flory et al.41 USA, 2002–2004 Population-based adult cases, 609 Risk factors for CAP OR
Farr et al.42 USA, 1982–1983 Population-based, case–control, 178:385 Risk factors for CAP OR
de Roux et al.43 Spain, 1997–2001 Population-based adult cases, 128:1165 Alcohol for CAP OR
Almirall et al.44 Spain, 1993–1995 Population-based, case–control, 205:475 Tobacco for CAP OR
Almirall et al.45 Spain, 1999–2000 Population-based, case–control, 1336:1326 Risk factors for CAP OR
IPD, invasive pneumococcal disease; CAP, community-acquired pneumonia; RR, relative risk; OR, odds ratio; DBT, diabetes; HR, hazard risk; COPD, chronic obstructive
pulmonary disease.
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Campbell.7 The hypothetical scenario of the concurrence of the
three conditions DBT + CHD + COPD showed an OR of 7.5 in four
of the seven articles (57%) and an OR of 4.5 in three of the seven
articles (43%) for which this co-occurrence in CAP could be
analyzed. In these groups of patients, the addition of another
common at-risk factor for CAP such as smoking (four concurrent
conditions) increased the OR calculated (2 to >40).
3.3. Conclusions
Because of the aging of the population and the association of
chronic diseases with advanced age, multimorbidity is expected to
become a common problem in adult populations (those aged >50
years).8–11 In this review, the prevalence of multimorbidity among
adult patients aged <65 years and 65 years ranged from
approximately 15% to 60% and from approximately 20% to
>90%, respectively.8,10–17,22–26 Not surprisingly, a number of
negative impacts of multimorbidity have been identiﬁed, associ-
ated with reduced health outcomes including functioning and
quality of life, more complex clinical management, speciﬁc health
care needs, and increased health care costs.8Figure 2. Multimorbidity in adults patients: prevalence of the most common at-risk
conditions (DBT, diabetes; CHD, chronic heart disease; COPD, chronic obstructive
pulmonary disease); 1Ref. 16; 2Ref. 24; 3Ref. 8; 4Ref. 26; 5Ref. 14.The most common disease clusters in older adults with
multimorbidity include several comorbidities deﬁned by the ACIP
as ‘at risk’ conditions signiﬁcantly associated with CAP and IPD (i.e.
DBT, CHD, and COPD). The relationship between multimorbidity
and the rates of all-cause CAP, pneumococcal CAP, and IPD among
adults have been analyzed by Shea et al.27 using three large health
care databases in the USA. The authors found that in adults aged
50–64 years, 19.6% had one at-risk condition, 4.4% had two, and
1.2% had three or more; the most common conditions were DBT
(49%), CHD (30%), and smoking (13%). In adults 65 years of age,
26.4% had one at-risk condition, 9.5% had two, and 3.1% had three
or more; the most common conditions were CHD (52%), DBT (50%),
and COPD (20%).27 In line with the publication of Shea et al.,27 in
the present review, the most common comorbid conditions
deﬁned by the ACIP as ‘at risk’ conditions of CAP/IPD were found
to be DBT, CHD, and COPD. In that regard, it was found that
individuals aged 55 years have DBT, CHD, and COPD as a unique
comorbidity in less than 30% of cases.12 The co-occurrence of these
three comorbid conditions (15–30% of cases) might reﬂect a
pathophysiological association among these risk factors.12,15,19 In
fact, the combinations of CHD + DBT, CHD + COPD, CHD + DBT,
COPD has been the most common cluster found by Weycker in
patients aged 50–54 years and 65 years with CAP or IPD.46
It is well-established that these types of comorbid condition
may occur together by chance in older people. The impact of this
co-occurrence on the risk of suffering certain illnesses (e.g. CAP) is
sometimes greater than the sum of the impacts of the individual
diseases.12 Stacking the individual ORs for each condition in the
same patient allows an estimation of the real probability of
suffering CAP or IPD (risk stacking).
The mathematical approach suggested by Campbell seems to be
the baseline value of the OR stacked.7 The classic model to calculate
the OR is described in terms of the log; what is additive on the log
scale is multiplicative on the linear scale. Thus if being in a
particular group increases the risk of PD three times for DBT and
being a smoker increases the risk by a factor of two, then if the two
risk factors are independent, someone in this group will have a risk
of 2  3 = 6 times that of someone without those risk factors.7 This
algebra is limited by the lack of adjustment related to the potential
interaction among the different conditions. This is a consequence
of the model if the two factors are independent. However, from a
clinical point of view, the association of conditions such as DBT,
Table 4
Scenarios of odds ratio stacked considering four common at-risk conditions for community-acquired pneumonia and invasive pneumococcal disease
CAP IPD
Type of study Population-based Case–control Population-based Case–control Case–control Population-based Case–control Case–control Case–control Case–control
Number 11 241 1952:2927 1628 1469:7345 1173:2346 2979 194:952 178:385 1336:1326 1282:12 785
Country Spain Australia USA UK USA USA USA USA Spain Finland
Ref. 29 Ref. 32 Ref. 33 Ref. 34 Ref. 38 Ref. 39 Ref. 40 Ref. 42 Ref. 45 Ref. 35
OR OR OR OR OR OR OR OR OR OR
At-risk conditions
DBT 2.91
(2.35–3.61)
1.22
(1.05–1.42)
1.45
(0.88–2.39)
1.07
(0.89–1.28)
1.3
(1.00–1.5)
1.13
(1.01–1.27)
ND 1.89
(0.62–5.70)
1.43
(1.11–1.92)
2.3
(1.6–3.5)
CHD 1.46
(1.16–1.84)
ND 1.78
(0.98–3.23)
1.37
(1.20–1.57)
5.2
(3.8–7.1)
1.48
(1.33–1.65)
1.80
(1.28–2.52)
3.24
(1.41–7.46)
1.81
(1.33–2.49)
2.8
(1.0–8.2)
COPD 1.82
(1.14–2.89)
2.41
(2.10–2.77)
1.66
(1.01–2.72)
1.35
(1.11–1.63)
2.5
(1.9–3.3)
1.21
(1.07–1.36)
3.84
(2.77–5.32)
4.40
(2.76–7.00)
2.96
(2.26–3.87)
ND
Scenario, two conditions
DBT+COPD 5.29
(2.67–10.43)
2.94
(2.20–3.93)
2.4
(0.88–6.5)
1.45
(0.98–2.08)
3.25
(1.9–4.5)
1.36
(1.08–1.72)
ND 8.3
(1.71–39.9)
4.2
(2.50–7.43)
ND
CHD+COPD 2.65
(1.32–5.31)
ND 2.95
(0.99–8.78)
1.85
(1.33–2.55)
13
(7.2–23.43)
1.8
(1.42–2.24)
6.9
(3.54–13.4)
14.2
(3.89–52.22)
5.4
(3.00–9.63)
ND
DBT+CHD 4.2
(2.72–6.64)
ND 2.6
(0.86–7.71)
1.5
(1.06–2.00)
6.8
(3.8–10.65)
1.7
(1.34–2.09)
ND 6.1
(0.87–45.52)
2.6
(1.47–4.78)
6.5
(1.6–28.7)
Scenario, three conditions
DBT+CHD+COPD 7.73
(3.10–19.1)
ND 4.2
(0.87–21)
1.98
(1.18–3.27)
16.9
(7.22–35.14)
2.02
(1.43–2.84)
ND 26.9
(2.41–297.65)
7.66
(3.33–18.50)
ND
Scenario, four conditions
Smoker 1.12
(0.83–1.49)
ND 1.48
(0.97–2.26)
0.99
(0.86–1.14)
2.5
(2.0–3.2)
1.31
(1.17–1.46)
2.06
(1.29–3.29)
1.84
(1.20–2.83)
1.34
(1.11–1.62)
ND
DBT+CHD+COPD+smoker 8.66
(2.57–28.4)
ND 6.3
(0.84–47.46)
1.96
(1.01–3.72)
42.25
(14.44–112.4)
2.65
(1.67–4.14)
14.2
(4.56–44.08)
49.5
(2.89–842.34)
10.26
(3.69–29.97)
ND
CAP, community-acquired pneumonia; IPD, invasive pneumococcal disease; OR, odds ratio; DBT, diabetes; CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; ND, not determined.
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and also IPD. The scenarios of risk stacking taking into account the
at-risk conditions for CAP and IPD (DBT, CHD, and COPD, with or
without another frequent risk factor (i.e. smoking)), show similar
ORs, mainly for CAP, to those observed in subjects classiﬁed as high
risk (5–10 to >40).
Limitations of this review result from the selection of studies,
heterogeneous nature of the subjects across studies, methods of
study analysis, interpretation of heterogeneity, and generalization
and application of the results. However, the conclusions on the
prevalence of multimorbidity in older patients and the impact of
risk stacking on the CAP/IPD incidence have the potential
advantage of being based on most existing evidence from relevant
studies.
In conclusion, the high prevalence of multimorbidity together
with the potential impact of the OR stacked on the probability of
suffering CAP and IPD are the reasons why the current classiﬁca-
tion for high-risk patients based only on the immune status of the
patient needs to be redeﬁned.
Conﬂict of interest: The authors are employed by Pﬁzer, Inc.
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